Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bhanu Visvalingam

Medical Oncology Orange City, FL Medical Doctor

NPI 1336132844 CMS profile 242315

2824 Enterprise Rd, Orange City, FL 32763

Open in the dashboard

General payments

$30,468

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$892,840 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Bhanu Visvalingam of Orange City, FL is reported in the CMS Open Payments database as having received $30,468 across 142 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $892,840 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,043 97
2024 General $34 1
2023 General $2,060 11
2022 General $144 3
2021 General $255 2
2020 General $114 1
2019 General $25,818 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bhanu Visvalingam
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Bhanu Visvalingam were reported at $2,043. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Bhanu Visvalingam Medical Oncology median Middle half National median
2019 $25,818 $968 $140–$6,658 $163
2020 $114 $747 $102–$5,891 $114
2021 $255 $430 $50–$4,098 $132
2022 $144 $812 $127–$4,907 $149
2023 $2,060 $957 $144–$5,248 $160
2024 $34 $1,042 $149–$5,650 $164
2025 $2,043 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tosoh Bioscience, Inc. $10,812 4 payments
  2. Celgene Corporation $7,300 13 payments
  3. Kite Pharma, Inc. $4,783 10 payments
  4. AstraZeneca Pharmaceuticals LP $3,779 8 payments
  5. Daiichi Sankyo Inc. $799 9 payments
  6. AstraZeneca UK Limited $723 7 payments
  7. Novartis Pharmaceuticals Corporation $244 10 payments
  8. Pfizer Inc. $188 8 payments
  9. Genentech USA, Inc. $163 2 payments
  10. Exelixis Inc. $160 2 payments
  11. Other $1,519 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $12,708 4 payments
  2. Gift $10,812 4 payments
  3. Food and Beverage $3,648 124 payments
  4. Travel and Lodging $2,940 9 payments
  5. Honoraria $360 1 payment
Products named General payments · program years 2019–2025
  1. Luspatercept $7,114 5 payments
  2. ST AIA-PACK Cystatin C Calibrator Set $5,406 2 payments
  3. FOL, AIA-PACK, Calibrator Set $5,406 2 payments
  4. Yescarta $4,783 10 payments
  5. CA 19-9, Sample Diluting Solution $2,703 1 payment
  6. FOL, AIA-PACK, Sample Diluting Solution $2,703 1 payment
  7. B12, AIA-PACK Sample Diluting Solution $2,703 1 payment
  8. CA19-9, ST AIA-PACK $2,703 1 payment
  9. Cystatin C, ST AIA-PACK $2,703 1 payment
  10. PA, AIA-PACK Linearity Set $2,703 1 payment
  11. Other $31,749 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record